In yesterday’s Wall Street session, Teva Pharmaceutical Industries Limited (NYSE:TEVA) shares traded at $8.13, up 0.74% from the previous session.
As of this writing, 12 analysts cover Teva Pharmaceutical Industries Limited (NYSE:TEVA). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $14.00 and a low of $7.00, we find $9.25. Given the previous closing price of $8.07, this indicates a potential upside of 14.62 percent. TEVA stock price is now -7.47% away from the 50-day moving average and -12.03% away from the 200-day moving average. The market capitalization of the company currently stands at $9.39B.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
There are 7 analysts who have given it a hold rating, whereas 1 have given it a buy rating. Brokers who have rated the stock have averaged $9.69 as their price target over the next twelve months.
With the price target enhanced from $10 to $12, Jefferies Downgraded its rating from Buy to Hold for Teva Pharmaceutical Industries Limited (NYSE: TEVA). On November 14, 2022, JP Morgan Downgraded its previous ‘Neutral’ rating to ‘Underweight’ on the stock reducing its target price from $11 to quote $10, while ‘UBS’ rates the stock as ‘Sell’.
In other news, Dethlefs Sven, EVP, North America Commercial sold 58,066 shares of the company’s stock on Mar 07. The stock was sold for $547,440 at an average price of $9.43. Upon completion of the transaction, the EVP, North America Commercial now directly owns 165,381 shares in the company, valued at $1.34 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 07, Exec. VP, European Commercial Daniell Richard sold 54,007 shares of the business’s stock. A total of $509,173 was realized by selling the stock at an average price of $9.43. This leaves the insider owning 69,770 shares of the company worth $0.57 million. Insiders disposed of 77,421 shares of company stock worth roughly $0.63 million over the past 1 year.
There have been several recent changes in the stakes of large investors in TEVA stock. A new stake in Teva Pharmaceutical Industries Limited shares was purchased by RUBRIC CAPITAL MANAGEMENT LP during the first quarter worth $36,583,000. SPHERA FUNDS MANAGEMENT LTD. invested $16,581,000 in shares of TEVA during the first quarter. In the first quarter, QUBE RESEARCH & TECHNOLOGIES LTD acquired a new stake in Teva Pharmaceutical Industries Limited valued at approximately $11,312,000. NORGES BANK acquired a new stake in TEVA for approximately $9,049,000. TRI LOCUM PARTNERS LP purchased a new stake in TEVA valued at around $8,231,000 in the second quarter. In total, there are 595 active investors with 49.60% ownership of the company’s stock.
Tuesday morning saw Teva Pharmaceutical Industries Limited (NYSE: TEVA) opened at $8.01. During the past 12 months, Teva Pharmaceutical Industries Limited has had a low of $6.78 and a high of $11.44. As of last week, the company has a debt-to-equity ratio of 2.63, a current ratio of 1.10, and a quick ratio of 0.70. The fifty day moving average price for TEVA is $8.75 and a two-hundred day moving average price translates $9.24 for the stock.
The latest earnings results from Teva Pharmaceutical Industries Limited (NYSE: TEVA) was released for Mar, 2023. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at $0.4, missing analysts’ expectations of $0.56 by -0.16. This compares to -$0.86 EPS in the same period last year. The net profit margin was -10.70% and return on equity was -19.10% for TEVA. The company reported revenue of $3.66 billion for the quarter, compared to $3.66 billion a year earlier. For the current quarter, analysts expect TEVA to generate $3.73B in revenue.
Moreover, the firm recently paid out its quarterly dividend on 12/12/2017. Investors who held shares on 11/28/2017 were paid a $0.085 dividend.
Teva Pharmaceutical Industries Limited(TEVA) Company Profile
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also manufactures and sells active pharmaceutical ingredients, as well as provides contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. In addition, it focuses on the central nervous system (CNS), pain, respiratory, and oncology areas. The company’s products portfolio in the CNS field comprises Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; and AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington’s disease and tardive dyskinesia; respiratory therapeutic area includes ProAir RespiClick, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease; and oncology therapeutic field consists of Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.
Leave a Reply